Top

Published in:

01-10-2019 | Breast Cancer | Epidemiology

Mammographic screening in male patients at high risk for breast cancer: is it worth it?

Authors: Maria Adele Marino, Ayca Gucalp, Doris Leithner, Delia Keating, Daly Avendano, Blanca Bernard-Davila, Elizabeth A. Morris, Katja Pinker, Maxine S. Jochelson

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Abstract

Purpose

To investigate the utility of mammography for breast cancer screening in a population of males at increased risk for breast cancer.

Methods

In this HIPAA-compliant institutional review board-approved single-institution study, mammography records and clinical data of 827 male patients who underwent digital mammography from September 2011–July 2018 were analyzed via the electronic medical record. 664 of these men presented with masses, pain, or nipple discharge and were excluded from this study. The remaining 163 asymptomatic men with familial and/or personal history of breast cancer, or with a known germline mutation in BRCA, underwent screening mammography and were included in this analysis.

Results

163 asymptomatic men (age: mean 63 years, range 24–87 years) underwent 806 screening mammograms. 125/163 (77%) had a personal history of breast cancer and 72/163 (44%) had a family history of breast cancer. 24/163 (15%) were known mutation carriers: 4/24 (17%) BRCA1 and 20/24 (83%) BRCA2. 792/806 (98%) of the screening mammograms were negative (BI-RADS 1 or 2); 10/806 (1.2%) were classified as BI-RADS 3, all of which were eventually downgraded to BI-RADS 2 on follow-up. 4/806 (0.4%) mammograms were abnormal (BI-RADS 4/5): all were malignant. The cancer detection rate in this cohort was 4.9 cancers/1000 examinations.

Conclusions

In our cohort, screening mammography yielded a cancer detection rate of 4.9 cancers/1000 examinations which is like the detection rate of screening mammography in a population of women at average risk, indicating that screening mammography is of value in male patients at high risk for breast cancer.

Liu N, Johnson KJ, Ma CX (2018) Male breast cancer: an updated surveillance, epidemiology, and end results data analysis. Clin Breast Cancer 18(5):e997–e1002CrossRefPubMed

Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol Off J Am Soc Clin Oncol 28:2114–2122. https://doi.org/10.1200/JCO.2009.25.5729 CrossRef

Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol Off J Am Soc Clin Oncol 22:735–742. https://doi.org/10.1200/JCO.2004.05.055 CrossRef

Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59. https://doi.org/10.1038/ng879 CrossRefPubMed

Evans DB, Crichlow RW (1987) Carcinoma of the male breast and Klinefelter’s syndrome: is there an association? CA Cancer J Clin 37:246–251CrossRefPubMed

Yu X-F, Feng W-L, Miao L-L et al (2013) The prognostic significance of molecular subtype for male breast cancer: a 10-year retrospective study. Breast Edinb Scotl 22:824–827. https://doi.org/10.1016/j.breast.2013.02.005 CrossRef

Piscuoglio S, Ng CKY, Murray MP et al (2016) The genomic landscape of male breast cancers. Clin Cancer Res Off J Am Assoc Cancer Res 22:4045–4056. https://doi.org/10.1158/1078-0432.CCR-15-2840 CrossRef

Vermeulen MA, Slaets L, Cardoso F et al (2017) Pathological characterisation of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Eur J Cancer Oxf Engl 82:219–227. https://doi.org/10.1016/j.ejca.2017.01.034 CrossRef

Cardoso F, Bartlett JMS, Slaets L et al (2018) Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol Off J Eur Soc Med Oncol 29:405–417. https://doi.org/10.1093/annonc/mdx651 CrossRef

10.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442 CrossRef

11.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2018) Genetic/familial high-risk assessment—breast and ovarian, version 1. https://www.tri-kobe.org/nccn/guideline/gynecological/english/genetic_familial.pdf. (n.d.)

12.

D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA et al (2013) ACR BI-RADS^® atlas, breast imaging reporting and data system. American College of Radiology, Reston, VA. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/BIRADS/BIRADS%20V5%20Changes.pdf. Accessed 20 Sep 2015

13.

Eccles DM, Evans DG, Mackay J (2000) Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). J Med Genet 37:203–209CrossRefPubMedPubMedCentral

14.

Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316. https://doi.org/10.1016/j.ejca.2010.02.015 CrossRefPubMed

15.

Vasen HF, Haites NE, Evans DG et al (1998) Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer Oxf Engl 34:1922–1926CrossRef

16.

Evans DGR, Lalloo F (2002) Risk assessment and management of high risk familial breast cancer. J Med Genet 39:865–871CrossRefPubMedPubMedCentral

17.

Eisinger F, Alby N, Bremond A et al (1998) Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol Off J Eur Soc Med Oncol 9:939–950CrossRef

18.

Warner E, Heisey RE, Goel V et al (1999) Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer. Can Fam Physician Med Fam Can 45:104–112

19.

Singer CF, Tea M-K, Pristauz G et al (2012) Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families. Wien Klin Wochenschr 124:334–339. https://doi.org/10.1007/s00508-012-0173-6 CrossRefPubMed

20.

Møller P, Evans G, Haites N et al (1999) Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Dis Mark 15:207–211CrossRef

21.

Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 23:8469–8476. https://doi.org/10.1200/JCO.2004.00.4960 CrossRef

22.

Leach MO, Boggis CRM, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet Lond Engl 365:1769–1778. https://doi.org/10.1016/S0140-6736(05)66481-1 CrossRef

23.

Kuhl C, Weigel S, Schrading S et al (2010) Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol Off J Am Soc Clin Oncol 28:1450–1457. https://doi.org/10.1200/JCO.2009.23.0839 CrossRef

24.

Brenner RJ, Weitzel JN, Hansen N, Boasberg P (2004) Screening-detected breast cancer in a man with BRCA2 mutation: case report. Radiology 230:553–555. https://doi.org/10.1148/radiol.2302030360 CrossRefPubMed

25.

Dershaw DD (1986) Male mammography. AJR Am J Roentgenol 146:127–131. https://doi.org/10.2214/ajr.146.1.127 CrossRefPubMed

26.

Dershaw DD, Borgen PI, Deutch BM, Liberman L (1993) Mammographic findings in men with breast cancer. AJR Am J Roentgenol 160:267–270. https://doi.org/10.2214/ajr.160.2.8424331 CrossRefPubMed

27.

Freedman BC, Keto J, Rosenbaum Smith SM (2012) Screening mammography in men with BRCA mutations: is there a role? Breast J 18:73–75. https://doi.org/10.1111/j.1524-4741.2011.01185.x CrossRefPubMed

28.

Mathew J, Perkins GH, Stephens T et al (2008) Primary breast cancer in men: clinical, imaging, and pathologic findings in 57 patients. Am J Roentgenol 191:1631–1639. https://doi.org/10.2214/AJR.08.1076 CrossRef

29.

Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 28:232–239. https://doi.org/10.1200/JCO.2009.23.8162 CrossRef

30.

Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602. https://doi.org/10.1038/nrc1670 CrossRefPubMed

31.

Fidler IJ (2003) The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nat Rev Cancer 3:453–458. https://doi.org/10.1038/nrc1098 CrossRef

32.

Hellman S (1994) Karnofsky memorial lecture. Natural history of small breast cancers. J Clin Oncol Off J Am Soc Clin Oncol 12:2229–2234. https://doi.org/10.1200/JCO.1994.12.10.2229 CrossRef

33.

Michaelson JS, Silverstein M, Wyatt J et al (2002) Predicting the survival of patients with breast carcinoma using tumor size. Cancer 95:713–723. https://doi.org/10.1002/cncr.10742 CrossRefPubMed

34.

Gibbs P, Onishi N, Sadinski M et al (2019) Characterization of sub-1 cm breast lesions using radiomics analysis. J Magn Reson Imaging 1:1. https://doi.org/10.1002/jmri.26732 CrossRef

35.

Sopik V, Narod SA (2018) The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat 170:647–656. https://doi.org/10.1007/s10549-018-4796-9 CrossRefPubMedPubMedCentral

36.

Mango V, Bryce Y, Morris EA et al (2018) Commentary ACOG practice bulletin July 2017: breast cancer risk assessment and screening in average-risk women. Br J Radiol 91:20170907. https://doi.org/10.1259/bjr.20170907 CrossRefPubMedPubMedCentral

37.

Expert Panel on Breast Imaging, Niell BL, Lourenco AP et al (2018) ACR appropriateness criteria^® evaluation of the symptomatic male breast. J Am Coll Radiol 15:S313–S320. https://doi.org/10.1016/j.jacr.2018.09.017 CrossRef

Title: Mammographic screening in male patients at high risk for breast cancer: is it worth it?
Authors: Maria Adele Marino
Ayca Gucalp
Doris Leithner
Delia Keating
Daly Avendano
Blanca Bernard-Davila
Elizabeth A. Morris
Katja Pinker
Maxine S. Jochelson
Publication date: 01-10-2019
Publisher: Springer US
Keywords: Breast Cancer
Mammography
Gynecomastia
Breast Cancer
Mammography
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05338-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Radiofrequency identification tag localization is comparable to wire localization for non-palpable breast lesions

The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer

Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers

Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II

Non-contrast MRI for breast screening: preliminary study on detectability of benign and malignant lesions in women with dense breasts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer